Novo Nordisk sues USPTO Director Dudas over rejected patent applications

According to Forbes (through AFX), Novo Nordisk AS is suing Jon Dudas, the director of the US Patent and Trademark Office [USPTO] asserting the USPTO has misinterpreted data, evidence and legislation in rejecting two patent applications. The technical area is the AERx inhaled insulin delivery system.

Typically, an unsuccessful patent applicant appeals to the Board (BPAI) and then if still unsuccesful may take the case to the CAFC.

The source for the story is the daily Boersen, which cited Lars Kjellberg, head of Novo Nordisk's patent unit.

Novo Nordisk's American affiliate is located in the Princeton area, right on US Route 1.